PABPC1 (Poly(A) Binding Protein Cytoplasmic 1)

This study identified six key genes regulating colorectal tumorigenesis and constructed a high-performance diagnostic model. These findings provide novel insights into the molecular mechanisms underlying the initiation and progression of CRC, and offer potential biomarkers and therapeutic targets for the clinical diagnosis and treatment of CRC.

Importantly, treatment with Eeyarestatin I, a small-molecule ER stress agonist, restored sunitinib sensitivity in tumor cells. These findings reveal a novel PABPC1-PGK1 regulatory axis underlying sunitinib resistance and suggest a promising therapeutic strategy for overcoming drug resistance in ccRCC.

Additionally, we observed significant positive correlations among NSUN2, YBX3, and ICAM-1 expression levels in NPC tissues, with their expression strongly associated with tumor progression and poor prognosis. Together, our findings reveal the crucial role of RNA m5C modification in EBV-associated NPC progression, delineate the LMP1/NSUN2/YBX3/ICAM-1 signaling cascade, and suggest this regulatory axis as a potential therapeutic target for NPC.

Patients with high DU showed diverse mutational characteristics, which may reflect the heterogeneous nature of MM and contribute to inferior survival outcomes.

Taken together, PABPC1 suppressed EOPE development through boosting trophoblast proliferation and invasion by elevating TMBIM4 mRNA stability. Our findings firstly elucidated the vital effect of PABPC1 on EOPE pathogenesis and highlighted that PABPC1 upregulation might be developed as a promising strategy for EOPE treatment.

Collectively, our findings demonstrate that hypoxia-induced PABP1/eIF4B LLPS specifically upregulates ChaC2 expression, enabling metastatic cancer cells to evade ferroptosis triggered by their own metastatic demands and ultimately facilitating tumor dissemination. This study uncovers a critical adaptive regulatory mechanism employed by metastatic GC cells to cope with stress challenges during PM, thereby offering novel therapeutic targets and strategic insights for intervention.

Disruption of this CELF1/eIF4E interaction inhibits both EMT induction in vitro and experimental metastasis in vivo. Our findings define a novel, non-canonical mode of translational regulation underlying cellular de-differentiation, raising the possibility that analogous non-canonical modes of translation impact additional transitional cellular states within development and disease.

Regarding clinical application, we identified micafungin as an inhibitor of UBE2M capable of suppressing the regulatory axis and, consequently, hindering CRC progression. Therefore, this study underscores the potential role of UBE2M in bridging neddylation with the cell cycle and holds promise for advancing targeted therapies in CRC treatment.

The most abundant "NYGYTF"-containing clones recognized MLANA, a tumor-associated antigen linked to prognosis and therapeutic responsiveness, underscoring its potential role in CRC progression. Collectively, these findings delineate cancer- and stage-specific TCR repertoire alterations and antigen specificities, highlighting novel biomarkers and therapeutic targets to inform TCR-based diagnostics and personalized immunotherapies in CRC and GC.

When loaded with penicillin, circAAGAB, or both, LTA-MSNs precisely targeted intratumoral S. mitis in ESCC patient-derived xenograft (PDX) models, demonstrating potent tumor-suppressive efficacy. Collectively, our findings reveal that intratumoral S. mitis critically drives ESCC tumorigenesis and represents a promising therapeutic target.

PABPC1 could serve as a potential prognostic biomarker for individuals with KIRP.

Further, RBPs like RPS8, RPL5, RPS3A, EEF1A1, and EIF4E1B were found to be strongly correlated with patients' overall survival. Taken together, our analyses identified several candidate RBPs which might serve as potential targets for oncological measures against gliomas.